share_log

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $32

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $32

高盛维持对Kiniksa Pharmicals的买入,将目标股价上调至32美元
Benzinga ·  2023/07/26 09:39

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $22 to $32.

高盛分析师保罗·崔维持Kiniksa Pharmicals(纳斯达克股票代码:KNSA)的买入,并将目标股价从22美元上调至32美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发